Skip to main content Accessibility help
×
Home

Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism

  • Rami Bou Khalil (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism
      Available formats
      ×

Abstract

Copyright

Corresponding author

*Address for correspondence: Rami Bou Khalil, MD, MSc, Saint Joseph University, Hôtel-Dieu de France, A. Naccache Boulevard (P.O. box: 166830), Achrafieh, Beiruth 16880, Lebanon. (Email: ramiboukhalil@hotmail.com)

References

Hide All
1. Tayeb, HO, Murad, HA, Rafeeq, MM, et al. Pharmacotherapy of schizophrenia: toward a metabolomic-based approach. CNS Spectr. [Epub ahead of print]. doi: 10.1017/S1092852918000962.
2. Bou Khalil, R. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses. 2011; 77(3): 427429.
3. Bou Khalil, R. Is insulin growth factor-1 the future for treating autism spectrum disorder and/or schizophrenia? Med Hypotheses. 2017; 99: 2325.
4. Riikonen, R. Treatment of autistic spectrum disorder with insulin-like growth factors. Eur J Paediatr Neurol. 2016; 20(6): 816823.
5. Rosenbloom, AL. Mecasermin (recombinant human insulin-like growth factor I). Adv Ther. 2009; 26(1): 4054.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed